Stelexis Therapeutics utilizes its proprietary TumorOrigin™ platform to isolate and maintain pre-cancerous and cancer stem cells for drug discovery. This technology addresses the challenge of identifying druggable targets on these cells, which are often responsible for cancer progression and treatment resistance.
Funding
$43M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail to eliminate pre-cancerous and cancer stem cells, which are key drivers of cancer progression, recurrence, and drug resistance. Identifying and studying these rare cells for drug discovery has been challenging due to difficulties in isolating, propagating, and maintaining them in a clinically relevant state.
Solution
Stelexis Therapeutics offers the TumorOrigin™ platform, a proprietary technology designed to isolate, expand, and maintain pre-cancerous and cancer stem cells derived from patient samples. This platform overcomes limitations such as insufficient cell count and poor cell survival, enabling unprecedented study of these cells for drug discovery. By providing access to clinically relevant stem cells, TumorOrigin™ facilitates the identification of novel, druggable targets on these cells, ultimately aiming to transform cancer treatment by targeting the tumor's origin. The platform utilizes large banks of patient-derived samples to ensure a representative and diverse cell population for research.
Target Audience
The primary audience includes pharmaceutical companies, biotechnology firms, and academic research institutions focused on cancer drug discovery and development.
Features
- Proprietary TumorOrigin™ platform for isolating and maintaining pre-cancerous and cancer stem cells.
- Utilizes large banks of patient-derived samples to ensure clinically relevant cell populations.
- Overcomes limitations of insufficient cell count and cell survival, enabling in-depth study.
- Facilitates the identification of novel, druggable targets on cancer stem cells.